Content
All Posts > Content under Healthcare
Conatus Pharmaceuticals Launches Small Offering For Pipeline Expansion
Article By:
Terry Chrisomalis
Read
Friday, May 12, 2017 7:05 PM EDT
The offering doesn’t seem to make sense after the Novartis (NVS) licensing deal being signed.
Sangamo Biosciences Continues Its Climb After Pfizer Partnership
Article By:
Terry Chrisomalis
Read
Friday, May 12, 2017 1:26 PM EDT
After yesterday's 60% gain, Sangamo climbed another 15% today on the potential of its Pfizer deal.
Capricor Therapeutics Tumbles 60% On Failed Heart Attack Trial
Article By:
Terry Chrisomalis
Read
Friday, May 12, 2017 12:15 PM EDT
Capricor Therapeutics reported an update on its phase 2 trial known as Allstar. It stated that the drug, CAP-1002 showed a low probability of achieving the primary endpoint of the study.
In this article: CAPR
Ardelyx Shares Plummet 37% Despite Passing Primary Endpoint Of Phase 3
Article By:
Terry Chrisomalis
Read
Friday, May 12, 2017 10:58 AM EDT
Ardelyx shares plummeted 37% despite passing the primary endpoint of a phase 3 study. The company tested its drug Tenapanor in phase 3, clinical trial known as T3MPO-1.
Ziopharm Oncology Announces Pricing Of $50 Million Follow-On Offering Of Common Stock
Article By:
NASDAQ GlobeNewswire
Read
Friday, May 12, 2017 10:18 AM EDT
Ziopharm Oncology today announced that it has priced an underwritten follow-on offering of 9,708,738 shares of its common stock at an offering price of $5.15 per share to a single institutional investor.
In this article: ZIOP
Aetna Inc - Chart Of The Day
Article By:
Jim Van Meerten
Read
Thursday, May 11, 2017 8:12 PM EDT
Since the Trend Spotter signaled a buy on 4/24 the stock gained 9.95%.
In this article: AET
Cannabis Now A Global Investment Opportunity
Article By:
Alan Brochstein
Read
Thursday, May 11, 2017 6:39 PM EDT
The Canadian market continues to evolve as a leader in the global cannabis industry, with legalization efforts likely to result in legal sales commencing in about a year.
Puma (PBYI) Q1 Loss Narrows, Focus Remains On Neratinib
Article By:
Zacks Investment Research
Read
Thursday, May 11, 2017 10:10 AM EDT
Puma Biotechnology, Inc. reported a first-quarter 2017 loss of $1.97 per share narrower than the Zacks Consensus Estimate of a loss of $2.08 and the year-ago loss of $2.19.
Teva Pharmaceutical Industries Ltd. (ADR) Backs Forecast Amid Mixed Q1
Article By:
Lorimer Wilson
Read
Thursday, May 11, 2017 10:00 AM EDT
The Israeli generic pharmaceutical giant, Teva Pharmaceutical Industries Ltd (ADR) posted mixed first quarter earnings but backed its full-year outlook, as a recent acquisition began to hugely bolster its top line.
In this article: TEVA
Consuming Oxygen
Article By:
Marvin R Clark
Read
Thursday, May 11, 2017 12:27 AM EDT
As US equity markets continue to price to perfection a grab bag of promised corporate giveaways, a group of researchers at the International Monetary Fund (IMF) had the temerity to ask last month – what could possibly go wrong.
Hologic Beats Q1 Sales And EPS
Article By:
Rod Raynovich
Read
Wednesday, May 10, 2017 10:28 PM EDT
Hologic's revenues Increased 3.2% and GAAP diluted Earnings Increased 666.7% Compared to Prior Year Period. The stock closed down 2% AH to $45.
4 Top-Ranked Liquid Stocks For A Winning Portfolio
Article By:
Zacks Investment Research
Read
Wednesday, May 10, 2017 3:04 PM EDT
Liquidity of a stock is an important yardstick that many investors tend to ignore. It primarily indicates a company’s capability to meet debt obligations by converting assets into liquid cash and equivalents.
